{"id":"W2567395185","doi":"10.1200/jco.2016.69.9538","title":"Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":219,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"Takeda Oncology; Genentech; National Cancer Institute; Onyx Pharmaceuticals; Incyte; Regeneron Pharmaceuticals; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Ovarian cancer; Internal medicine; Fallopian tube; Adverse effect; Gastroenterology; Fallopian tube cancer; Response Evaluation Criteria in Solid Tumors; Population; Nausea; Phases of clinical research; Folate receptor; Oncology; Cancer; Surgery; Chemotherapy; Cancer cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001526629,0.0005888464,0.0009073162,0.0001894277,0.0002870894,0.0004411062,0.0003748027,0.0003558093,0.00116986],"category_scores_gemma":[0.001037439,0.0002810149,0.0007151905,0.0002213391,0.0004658359,0.0003946503,0.0002753951,0.001084015,0.0002326192],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006760629,"about_ca_system_score_gemma":0.001030131,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009066236,"about_ca_topic_score_gemma":0.001981183,"domain_scores_codex":[0.9995498,0.0001965762,0.00002235919,0.00008943906,0.00008038426,0.00006134601],"domain_scores_gemma":[0.9994369,0.0000812868,0.0001353137,0.00006573647,0.00004599555,0.0002346978],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3366757,0.03708902,0.2447824,0.0005628014,0.001685035,0.0009643942,0.000677822,0.005071259,0.1507292,0.0002100744,0.003737294,0.2178151],"study_design_scores_gemma":[0.07450643,0.5607392,0.3313445,0.00004513273,0.001168923,0.001849083,0.0002227965,0.003978003,0.01887463,0.0001962235,0.007022286,0.00005283691],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9985726,0.0003086765,0.0001819155,0.00004425614,0.000008012174,0.0002710596,0.0002106322,0.00001350045,0.0003894359],"genre_scores_gemma":[0.9977701,0.0002327166,0.0004037921,0.0001569025,0.00002025044,0.0002038339,0.000677334,0.000006586148,0.0005286396],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001526629,"threshold_uncertainty_score":0.008073628,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08803792109366386,"score_gpt":0.4750723308384164,"score_spread":0.3870344097447526,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}